Copyright Reports & Markets. All rights reserved.

Covid-19 Impact on Pulmonary Drugs Market, Global Research Reports 2020-2021

Request for Sample of this report
Buy now
  • 1.1 Research Scope
  • 1.2 Market Segmentation
  • 1.3 Research Objectives
  • 1.4 Research Methodology
    • 1.4.1 Research Process
    • 1.4.2 Data Triangulation
    • 1.4.3 Research Approach
    • 1.4.4 Base Year
  • 1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
    • 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
    • 1.5.2 Covid-19 Impact: Commodity Prices Indices
    • 1.5.3 Covid-19 Impact: Global Major Government Policy
  • 1.6 The Covid-19 Impact on Pulmonary Drugs Industry
  • 1.7 COVID-19 Impact: Pulmonary Drugs Market Trends

    • 2 Global Pulmonary Drugs Quarterly Market Size Analysis

    • 2.1 Pulmonary Drugs Business Impact Assessment - COVID-19
      • 2.1.1 Global Pulmonary Drugs Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
      • 2.1.2 Global Pulmonary Drugs Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
    • 2.2 Global Pulmonary Drugs Quarterly Market Size 2020-2021
    • 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
      • 2.3.1 Drivers
      • 2.3.2 Restraints
      • 2.3.3 Opportunities
      • 2.3.4 Challenges

    3 Quarterly Competitive Assessment, 2020

    • 3.1 Global Pulmonary Drugs Quarterly Market Size by Manufacturers, 2019 VS 2020
    • 3.2 Global Pulmonary Drugs Factory Price by Manufacturers
    • 3.3 Location of Key Manufacturers Pulmonary Drugs Manufacturing Factories and Area Served
    • 3.4 Date of Key Manufacturers Enter into Pulmonary Drugs Market
    • 3.5 Key Manufacturers Pulmonary Drugs Product Offered
    • 3.6 Mergers & Acquisitions, Expansion Plans

    4 Impact of Covid-19 on Pulmonary Drugs Segments, By Type

    • 4.1 Introduction
      • 1.4.1 Inhaled Corticosteroids
      • 1.4.2 Long Acting Beta-2 Agonists
      • 1.4.3 Antihistamines
      • 1.4.4 Vasodilators
      • 1.4.5 Others
    • 4.2 By Type, Global Pulmonary Drugs Market Size, 2019-2021
      • 4.2.1 By Type, Global Pulmonary Drugs Market Size by Type, 2020-2021
      • 4.2.2 By Type, Global Pulmonary Drugs Price, 2020-2021

    5 Impact of Covid-19 on Pulmonary Drugs Segments, By Application

    • 5.1 Overview
      • 5.5.1 Asthma & COPD
      • 5.5.2 Allergic Rhinitis
      • 5.5.3 Pulmonary Arterial Hypertension
      • 5.5.4 Cystic Fibrosis
      • 5.5.5 Others
    • 5.2 By Application, Global Pulmonary Drugs Market Size, 2019-2021
      • 5.2.1 By Application, Global Pulmonary Drugs Market Size by Application, 2019-2021
      • 5.2.2 By Application, Global Pulmonary Drugs Price, 2020-2021

    6 Geographic Analysis

    • 6.1 Introduction
    • 6.2 North America
      • 6.2.1 Macroeconomic Indicators of US
      • 6.2.2 US
      • 6.2.3 Canada
    • 6.3 Europe
      • 6.3.1 Macroeconomic Indicators of Europe
      • 6.3.2 Germany
      • 6.3.3 France
      • 6.3.4 UK
      • 6.3.5 Italy
    • 6.4 Asia-Pacific
      • 6.4.1 Macroeconomic Indicators of Asia-Pacific
      • 6.4.2 China
      • 6.4.3 Japan
      • 6.4.4 South Korea
      • 6.4.5 India
      • 6.4.6 ASEAN
    • 6.5 Rest of World
      • 6.5.1 Latin America
      • 6.5.2 Middle East and Africa

    7 Company Profiles

    • 7.1 Sanofi SA
      • 7.1.1 Sanofi SA Business Overview
      • 7.1.2 Sanofi SA Pulmonary Drugs Quarterly Production and Revenue, 2020
      • 7.1.3 Sanofi SA Pulmonary Drugs Product Introduction
      • 7.1.4 Sanofi SA Response to COVID-19 and Related Developments
    • 7.2 Meda Pharmaceuticals
      • 7.2.1 Meda Pharmaceuticals Business Overview
      • 7.2.2 Meda Pharmaceuticals Pulmonary Drugs Quarterly Production and Revenue, 2020
      • 7.2.3 Meda Pharmaceuticals Pulmonary Drugs Product Introduction
      • 7.2.4 Meda Pharmaceuticals Response to COVID-19 and Related Developments
    • 7.3 Circassia Pharmaceuticals Plc.
      • 7.3.1 Circassia Pharmaceuticals Plc. Business Overview
      • 7.3.2 Circassia Pharmaceuticals Plc. Pulmonary Drugs Quarterly Production and Revenue, 2020
      • 7.3.3 Circassia Pharmaceuticals Plc. Pulmonary Drugs Product Introduction
      • 7.3.4 Circassia Pharmaceuticals Plc. Response to COVID-19 and Related Developments
    • 7.4 AstraZeneca Plc.
      • 7.4.1 AstraZeneca Plc. Business Overview
      • 7.4.2 AstraZeneca Plc. Pulmonary Drugs Quarterly Production and Revenue, 2020
      • 7.4.3 AstraZeneca Plc. Pulmonary Drugs Product Introduction
      • 7.4.4 AstraZeneca Plc. Response to COVID-19 and Related Developments
    • 7.5 GlaxoSmithKline Plc.
      • 7.5.1 GlaxoSmithKline Plc. Business Overview
      • 7.5.2 GlaxoSmithKline Plc. Pulmonary Drugs Quarterly Production and Revenue, 2020
      • 7.5.3 GlaxoSmithKline Plc. Pulmonary Drugs Product Introduction
      • 7.5.4 GlaxoSmithKline Plc. Response to COVID-19 and Related Developments
    • 7.6 Mallinckrodt Pharmaceuticals Plc.
      • 7.6.1 Mallinckrodt Pharmaceuticals Plc. Business Overview
      • 7.6.2 Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Quarterly Production and Revenue, 2020
      • 7.6.3 Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Product Introduction
      • 7.6.4 Mallinckrodt Pharmaceuticals Plc. Response to COVID-19 and Related Developments
    • 7.7 Cheisi Farmaceutici S.p.A
      • 7.7.1 Cheisi Farmaceutici S.p.A Business Overview
      • 7.7.2 Cheisi Farmaceutici S.p.A Pulmonary Drugs Quarterly Production and Revenue, 2020
      • 7.7.3 Cheisi Farmaceutici S.p.A Pulmonary Drugs Product Introduction
      • 7.7.4 Cheisi Farmaceutici S.p.A Response to COVID-19 and Related Developments
    • 7.8 Zambon Company S.p.A
      • 7.8.1 Zambon Company S.p.A Business Overview
      • 7.8.2 Zambon Company S.p.A Pulmonary Drugs Quarterly Production and Revenue, 2020
      • 7.8.3 Zambon Company S.p.A Pulmonary Drugs Product Introduction
      • 7.8.4 Zambon Company S.p.A Response to COVID-19 and Related Developments
    • 7.9 Alaxia SAS
      • 7.9.1 Alaxia SAS Business Overview
      • 7.9.2 Alaxia SAS Pulmonary Drugs Quarterly Production and Revenue, 2020
      • 7.9.3 Alaxia SAS Pulmonary Drugs Product Introduction
      • 7.9.4 Alaxia SAS Response to COVID-19 and Related Developments
    • 7.10 Merck Sharp & Dohme Limited
      • 7.10.1 Merck Sharp & Dohme Limited Business Overview
      • 7.10.2 Merck Sharp & Dohme Limited Pulmonary Drugs Quarterly Production and Revenue, 2020
      • 7.10.3 Merck Sharp & Dohme Limited Pulmonary Drugs Product Introduction
      • 7.10.4 Merck Sharp & Dohme Limited Response to COVID-19 and Related Developments

    8 Supply Chain and Sales Channels Analysis

    • 8.1 Pulmonary Drugs Supply Chain Analysis
      • 8.1.1 Pulmonary Drugs Supply Chain Analysis
      • 8.1.2 Covid-19 Impact on Pulmonary Drugs Supply Chain
    • 8.2 Distribution Channels Analysis
      • 8.2.1 Pulmonary Drugs Distribution Channels
      • 8.2.2 Covid-19 Impact on Pulmonary Drugs Distribution Channels
      • 8.2.3 Pulmonary Drugs Distributors
    • 8.3 Pulmonary Drugs Customers

    9 Key Findings

      10 Appendix

      • 10.1 About Us

      This report covers market size and forecasts of Pulmonary Drugs, including the following market information:
      Global Pulmonary Drugs Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
      Global Pulmonary Drugs Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
      Global Pulmonary Drugs Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
      Global Pulmonary Drugs Market Size by Company, 2019- 2020 (quarterly data), (US$ Million) & (K Units)

      Key market players
      Major competitors identified in this market include Sanofi SA, Meda Pharmaceuticals, Circassia Pharmaceuticals Plc., AstraZeneca Plc., GlaxoSmithKline Plc., Mallinckrodt Pharmaceuticals Plc., Cheisi Farmaceutici S.p.A, Zambon Company S.p.A, Alaxia SAS, Merck Sharp & Dohme Limited, etc.

      Based on the Region:
      Asia-Pacific (China, Japan, South Korea, India and ASEAN)
      North America (US and Canada)
      Europe (Germany, France, UK and Italy)
      Rest of World (Latin America, Middle East & Africa)

      Based on the Type:
      Inhaled Corticosteroids
      Long Acting Beta-2 Agonists
      Antihistamines
      Vasodilators
      Others

      Based on the Application:
      Asthma & COPD
      Allergic Rhinitis
      Pulmonary Arterial Hypertension
      Cystic Fibrosis
      Others

      Buy now